Merck (MRK) Liabilities from Discontinued Operations (2014 - 2020)
Merck (MRK) posted quarterly Liabilities from Discontinued Operations of 1086000000.0 for Q4 2020, up 34.07% sequentially from 810000000.0 in Q3 2014.
Merck (MRK) Liabilities from Discontinued Operations (2014 - 2020) Analysis & Trends
Merck has disclosed Liabilities from Discontinued Operations across 2 years of filings, most recently posting 1086000000.0 for Q4 2020.
- In Q4 2020, Liabilities from Discontinued Operations changed N/A year-over-year to 1086000000.0; the TTM figure through Dec 2020 stood at 1086000000.0 (changed N/A YoY), while the FY2020 annual figure was 1086000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations grew to 1086000000.0 in Q4 2020, from 810000000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for MRK reached as high as 1086000000.0 in Q4 2020 and fell as low as 1086000000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.09 Bn |
| Dec 31, 2020 | 1.09 Bn |
| Sep 30, 2014 | 810.00 Mn |
| Sep 30, 2014 | 810.00 Mn |
| Jun 30, 2014 | 801.00 Mn |
| Jun 30, 2014 | 801.00 Mn |
| Mar 31, 2014 | 848.00 Mn |
| Mar 31, 2014 | 848.00 Mn |